The expression of the P2Y


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
16 04 2020
Historique:
received: 10 01 2020
accepted: 29 01 2020
pubmed: 11 2 2020
medline: 21 10 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

Inflammatory bowel disease (IBD) is a risk factor for the development of colorectal cancer (CRC) for which mutation to p53 is an early event leading to dysplasia. Interestingly, P2RY6 mRNA increases in both pathologies. In this study, we investigated if p53 and p53

Identifiants

pubmed: 32037085
pii: S0006-291X(20)30246-1
doi: 10.1016/j.bbrc.2020.01.161
pii:
doi:

Substances chimiques

Neoplasm Proteins 0
Receptors, Purinergic P2 0
Tumor Suppressor Protein p53 0
purinoceptor P2Y6 0
Luciferases EC 1.13.12.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

798-802

Subventions

Organisme : CIHR
ID : MOP-286567
Pays : Canada

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Caroline M Molle (CM)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: caroline.molle@usherbrooke.ca.

Guillaume Arguin (G)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: guillaume.arguin@usherbrooke.ca.

Charlotte Jemfer (C)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: c.jemfer@hubebi.com.

Morgane Placet (M)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: morgane.placet@usherbrooke.ca.

Steve Dagenais Bellefeuille (S)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: steve.dagenais.bellefeuille@usherbrooke.ca.

Fernand-Pierre Gendron (FP)

Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Pavillon of Applied Research on Cancer, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada. Electronic address: fernand-p.gendron@usherbrooke.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH